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E-mail: knut.stieger@uniklinikum-giessen.deCommon genome-editing strategies are either based on non-
homologous end joining (NHEJ) or, in the presence of a tem-
plate DNA, based on homologous recombination with long
(homology-directed repair [HDR]) or short (microhomology-
mediated end joining [MMEJ]) homologous sequences. In the
current study, we aim to develop a model system to test the ac-
tivity of MMEJ after CRISPR/Cas9-mediated cleavage in cell
culture. Following successful proof of concept in an episomally
based reporter system, we tested template plasmids containing
a promoter-less luciferase gene ﬂanked by microhomologous
sequences (mhs) of different length (5, 10, 15, 20, 30, and
50 bp) that are complementary to the mouse retinitis pigmen-
tosa GTPase regulator (RPGR)-ORF15, which is under the
control of a CMV promoter stably integrated into a HEK293
cell line. Luciferase signal appearance represented successful
recombination events and was highest when the mhs were
5 bp long, while longer mhs revealed lower luciferase signal.
In addition, presence of Csy4 RNase was shown to increase
luciferase signaling. The luciferase reporter system is a valuable
tool to study the input of the different DNA repair mechanisms
in the replacement of large DNA sequences by mhs.
INTRODUCTION
Programmable nucleases, such as TALENs and the CRISPR/Cas
system, enable speciﬁc genome engineering. A cleavage at the desired
genome position activates the endogenous cell repair machinery,
which generates various gene modiﬁcations.1–4 Two main repair
pathways are well characterized: non-homologous end joining
(NHEJ), which is an error-prone mechanism to induce knockouts;
and homology-directed repair (HDR) with a deﬁned DNA donor
template, which is mainly used for gene knockins and speciﬁc gene
modiﬁcations.5–8 Gene therapy strategies that are aimed at correcting
the disease-causing mutations are currently based on HDR events.
While physiologically, the sister chromatid serves as a repair template
for HDR during the G2 cell-cycle stage, a targeting vector as a tem-
plate is used for therapeutic gene-editing strategies. HDR events
with exogenous templates have been reported in several cell lines
and organisms, with differences concerning their efﬁciencies andMolecular T
This is an open access article under the CC BY-NC-generally being at much lower levels than NHEJ events.9–11 One of
the major challenges in advancing genome editing based on HDR is
that this repair pathway is active almost exclusively during the late
S/G2 phase, whereas NHEJ, which needs to be avoided in such
strategies, is active throughout the cell cycle12 (Figure 1A).
More recently, an alternative NHEJ (A-NHEJ) pathway has been
described, which was re-named microhomology-mediated end
joining (MMEJ). Short microhomologies (currently considered to
be within a 5–25 bp range) ﬂanking a double strand break (DSB)
can recombine to each other through this process, resulting in
deletions in between the homology arms13,14 (Figure 1B). MMEJ in
combination with targeting vectors can also be used as a powerful
technology for precise gene knockins.15,16 The efﬁciency is strongly
dependent on the length of the microhomologous sequences (mhs);
15 bp and longer was reported to result in a signiﬁcant number of
integration events.17 MMEJ seems to be most active during the
M and early S phases in dividing cells,12,18 and is associated with
the presence of HDR- and NHEJ-independent proteins.19,20 Because
this repair pathway is mostly active in a different cell-cycle stage
compared with HDR and is mechanistically associated with proteins
not involved in HDR or NHEJ, this pathway may represent an
alternative approach for developing therapeutic genome-editing
applications.
The terminal exon ORF15 of the retinitis pigmentosa GTPase regu-
lator (RPGR) gene, in which over 300 different mutations cause
X-linked retinitis pigmentosa (XLRP),21,22 may represent an ideal
target locus to replace a mutant exon by the respective wild-type
exon. In a ﬁrst step, we developed a universal reporter-gene-based
system to study MMEJ mechanisms in order to optimize the replace-
ment efﬁciency of deﬁned DNA sequences within the ORF15 exon.herapy: Nucleic Acids Vol. 11 June 2018 ª 2018 The Authors. 407
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Double-Strand Break Repair Events
(A) Scheme showing the three preferred repair mecha-
nisms during the cell cycle after DNA double-strand break.
The error-prone NHEJ is active during thewhole cell cycle.
HDR leads to correct repair in late S/G2 phases. The
MMEJ repair is active in early M and S phases, and can
be used for targeted insertions with small homolog
sequences. (B) Scheme of the different repair events
highlighting the importance and length of the homologous
sequences on the donor template DNA. For HDR,
homologous regions of more than 100 bp up to several
kbp are needed to edit a given sequence, depending on
the size of the sequence to be replaced. For MMEJ, the
length of the homologous sequences is about 5–25 bp.
Molecular Therapy: Nucleic AcidsExploiting the advantages of the CRISPR/Cas system, we were able to
induce several DSBs simultaneously to trigger MMEJ.23,24 Besides
this, our reporter system may provide a tool in the future to gain
more insights into cell-speciﬁc repair efﬁciencies in combination
with different gene therapy strategies.
RESULTS
18-bp Microhomology Is Sufficient to Trigger MMEJ in an
Episomal System
We detected MMEJ events in HEK293 cells in an episomal-based
assay (Figure 2). The acceptor plasmid (AP) in the reporter system
consists of a GFP gene under the control of a CMV promoter and
an SV40 polyadenylation signal ﬂanked by two different 18-bp mhs
(Figure 2B). The donor plasmid (DB) harbors identical mhs ﬂanking
a blue ﬂuorescent protein (BFP) gene, which is inactive due to the
absence of a promoter sequence. Next to the mhs, one (DB1, AP1)
or two (DB2, AP2) Cas9 sites are incorporated for cleavage (Fig-
ure 2B). These target sites represent two different but therapeutically
relevant sequences within the ORF15 of the RPGR gene (Table 1). The
guide RNAs (gRNAs 1 and 2) and the Cas9 (px459) sequences were
provided as separate plasmids (Figure 2A). The episomal-based assay
showed signiﬁcantly higher BFP levels compared with control sam-
ples without induced Cas9 cleavage (Figure 2C). Interestingly, the
number of BFP-positive cells was about 6%–7%, regardless of whether
one or two Cas9 target sites were included in each vector, indicating
that a pathway other than NHEJ was active. If NHEJ would have
resulted in the edited gene, the BFP signaling would differ between
the combinations AP1+DB1 and AP1+DB2, as the former would
have the SV40 polyadenylation signal not in close proximity to the
BFP gene following recombination, because of the integration of
the entire plasmid backbone (Figure 2B).
Application to the RPGR ORF15 Exon
The RPGR gene produces two major isoforms: one being a constitu-
tively expressed form containing exons 1–19; and a second form
expressing exons 1–13 and a terminal exon, commonly referred to
as ORF15. The ORF15 exon contains 80% of all disease-causing
mutations found in XLRP (Figure 3A). Therefore, the replacement
of most of the ORF15 sequence would represent a single therapeutic
approach for a large number of patients. To study the MMEJ mech-408 Molecular Therapy: Nucleic Acids Vol. 11 June 2018anism at the genomic level, we generated a stable HEK293 cell line
containing the murine RPGR-ORF15 sequence under the control of
a CMV promoter. The DNA sequence, which would serve as mhs,
ﬂanking the ORF15 was chosen with a distance of 30 bp to the
Cas9 cleavage site. This distance was chosen to avoid indels formation
within themhs, which could be potentially induced by NHEJ activities
following DSB induction (Figure 3B). The donor vector contains the
luciferase gene lacking promotor sequences ﬂanked by the mhs
(length 5, 10, 15, 20, 30, and 50 bp) (Figure 6A). The Cas9 target sites
ﬂank the mhs in a way that either a short (6 bp, PAMin) or a long
overhang (17 bp, PAMout) results after cleavage (Figure 3B).
The luciferase expression was veriﬁed 48 hr following transfection
(Figure 4A). A band at the expected size was visible only in the lane
with cell lysate that was transfected with gRNAs, template, and
Cas9 protein. By using the PAMin variant, 20-bp mhs length, and
different ratios of the plasmids, we were able to show ﬁve times higher
luciferase signal compared with control samples (Figure 4B), indi-
cating that DSB repair takes place at the site. Interestingly, our data
show that a DSB in the donor template is a prerequisite for recombi-
nation events to take place, because the control experiment with
donor vector, Cas9, and gRNAs 1 and 2 (only cutting within the target
genome) did not show any increased signal compared with donor
template transfection alone. This could indicate NHEJ being the
major repair mechanism. Following this, we compared the PAMin
variant with the highest luciferase signal to the respective PAMout
variant, again with 20-bp mhs length. We observed that the luciferase
signal increased by 100% (Figure 4C). This observation, in turn, indi-
cates that NHEJ is not the major repair mechanism because luciferase
signal strength would not have been dependent on the position of
cleavage.
The 50 Cleavage Is More Important Than the 30 Cleavage to
Trigger MMEJ
In order to investigate which repair mechanism is active in the model
system, we analyzed whether a double cleavage or a linearization of
the donor vector propagates high genome-editing efﬁciency. A cleav-
age upstream (50 end) of the luciferase gene resulted in a similar lucif-
erase signal compared with a cut at both sides of the gene, while a
single cut downstream (30 end) of the gene did not result in a
Figure 2. Episomal-Based MMEJ Assay
(A) The plasmids used in this assay. pSQT1313 harbors gRNAs from therapeutic relevant target sequences. The px459 plasmid encodes only the Cas9 protein in the
episomal-based assays. For the genomic editing experiments it harbors gRNA3 resp. gRNA4. (B) Schematic overview of plasmid combinations to induce MMEJ recom-
bination events. The donor plasmid (DB) harbors a complete BFP plasmid without promotor. BFP is flanked by 18-bp microhomology regions (orange and purple), and the
plasmid can be linearized (DB1) or the insert can be cleaved out (DB2). The AP was generated following the same principle. The Cas9 cleavage occurs in a PAMout manner
(cf. Figure 3). (C) Episomal gene-editing efficiencies measure by quadruple transfections of the reporter plasmids. Depicted is the number of BFP-positive cells after DNA
repair. Error bars indicate the SD of the data set.
www.moleculartherapy.orgsigniﬁcant amount of luciferase signal (Figure 4D). The observation
that only one cut in the donor template upstream of the luciferase
gene is necessary to generate high luciferase signal suggests that
MMEJ takes place. If NHEJ would have occurred after the single
cut, the resulting luciferase signal would be much lower because of
the incorporation of the entire plasmid backbone, disrupting the
connection between luciferase gene and bovine growth hormone
(BGH) polyadenylation signal.
Addition of RNases Increases DNA Repair Efficacy
We also analyzed whether supplementary RNases would be superior
for the processing of the RNA transcripts into gRNAs, which wouldTable 1. Guide RNA Sequences
Guide RNA Sequence 50/30
gRNA used in episomal-based
assay
TCGAACTTTGGGAAAAATCTGG
gRNA used in episomal-based
assay and gRNA1
GTCAGGGATACCAGAGGAGCAGG
gRNA g2 TCCAGAATCGTTCGGAGCCTAGG
gRNA g3 GAGCGCCACCATGGTGAGCAAGG
gRNA g4 GGCCACAAGTTCAGCGTGTCCGG
List of the gRNA sequences that have been used during the experimentation. Underlined
sequences represent the PAM (protospacer adjacent motif) site.be an important aspect in therapeutic applications. Because the
plasmid pSQT1313 harboring the gRNA 1+2 contains Csy4 RNase
sites in between the two RNA sequences (Figure 2A), we were able
to study DNA repair activities with and without the addition of
Csy4-expressing plasmids to the transfections.25 Interestingly, an
addition of the enzyme further increased the DNA repair activity
by 100% (Figure 5), indicating that even though eukaryotic RNases
are able to process guide RNases, the efﬁciency of DSB repair events
in a therapeutic setting may be improved by the addition of RNA-pro-
cessing enzymes.
5-bp mhs Length Is Most Efficient to Trigger MMEJ
Finally, we studied whether the mhs length would have an impact on
the luciferase signal intensity after MMEJ (Figure 6A). We found
signiﬁcantly higher luciferase signal with all different mhs (5, 10,
15, 20, 30, 50) tested compared with negative control (Figure 6B).
The intensity of the RLU for the different microhomology pairs varied
between 153.268 ± 17.387 and 16.874 ± 5.985 RLU. The 5-bp micro-
homology donor plasmid showed the maximum RLU followed by 15,
30, 20, 50, and 10 bp.
DISCUSSION
In this study, we developed an in vitro model system to study
MMEJ at the locus of the RPGR gene on chromosome X, in which
mutations are associated with XLRP. We showed that homologous
recombination can take place at the target site with mhs rangingMolecular Therapy: Nucleic Acids Vol. 11 June 2018 409
Figure 3. DNA Repair Reporter System in Stable
HEK293-mORF15 Cells
(A) X-linked retinitis pigmentosa is associated with muta-
tions in the RPGR gene. The terminal ORF15 exon with its
repetitive sequences is a mutational hotspot with almost
300 known disease-causing mutations. A large part from
ORF15 has been cloned into HEK293 cells as indicated by
dashed lines. (B) Schematic representation of the MMEJ
model system. The ORF15 sequence was almost entirely
cloned between a CMV promoter and a BGH poly-
adenylation signal and stable integrated into the HEK293
cell line. Blue and green squares indicate the micro-
homologous regions (mhs). Vertical black lines indicate
the guide RNA target sites g1 to g2. Stars indicate a buffer
zone of 30 bp between the gRNA sites and the mhs. The
template plasmid contains the luciferase cDNA flanked by
two mhs and gRNA target sites 3 and 4. The orientation is
either PAMout, when the polyspacer adjacent motif (PAM)
is 17 bp away from the gRNA target site, or PAMin, when
the PAM is only 6 bp away. iaLuc PAMout, inactive lucif-
erase template PAMout; iaLuc PAMin, inactive luciferase
template PAMin. Upon cleavage and recombination, the
luciferase cDNA is integrated at the ORF15 locus, and the
CMV promoter drives transgene expression.
Molecular Therapy: Nucleic Acidsfrom 5 to 50 bp in length. Interestingly, mhs with 5-bp length was
most efﬁcient.
Until recently, it was considered that high-ﬁdelity genome editing is
generally based on HDR events. Unfortunately, this major knockin
strategy shows different success rates depending on locus, nuclease,
cell types, and organisms.26–28 Sakuma and colleagues16 demon-
strated that precise knockin experiments are possible with short
homologies based on the MMEJ repair pathway. One advantage is
that MMEJ donor templates do not need large homology regions,
as this is the case for donor templates for HDR-based editing with
very long homology arms (Figure 1). Even though single-stranded oli-
godeoxynucleotide (ssODN) can also be used as templates for HDR,
this option is only used to edit the genome with small modiﬁcations
(<100 bp) and is not suitable for the insertion of long DNA sequences,
as it would be the case when replacing the ORF15 exon.29–31 The
NHEJ pathway is also an option to incorporate exogenous sequences,
but this pathway is error prone by inducing mutagenic in-dels. There-
fore, NHEJ is most often used to generate knockouts, for which no
exogenous template is needed.26,32,33 Consequently, MMEJ may
represent an alternative way to HDR-based genome editing to replace
larger DNA sequences of choice.410 Molecular Therapy: Nucleic Acids Vol. 11 June 2018Although MMEJ and HDR are the repair path-
ways of choice to replace mutant DNA by
wild-type DNA, it is often difﬁcult to discern
by which repair event a DSB was processed. In
our model system, we consider the short homol-
ogy arms as the key elements for MMEJ to take
place, as it was reported in several studies
that HDR for larger sequences to be replaced re-quires homology arms way beyond 100 bp of length.10,11,16 Of note,
we observed an overall decline in replacement activity with longer
mhs, which could well be due to a shift from MMEJ activity more
toward an HDR-dependent repair mechanism. This question is
currently addressed by the authors by knocking down/out respective
repair proteins.
NHEJ and the two homology-dependent pathways are always
competing on the DNA ends following a DSB. The processing of nu-
cleotides (removal or adding) at the target site is a characteristic
feature of the NHEJ mechanism. A few nucleotides in the luciferase
donor vector with its Cas9 PAMin and PAMout sites can be deleted
after Cas9 cleavage through NHEJ. However, the PAMin site has
only a 6-bp distance between the Cas9 cleavage site and the mhs.
Larger deletions will directly interfere with themhs, which inﬂuences
the MMEJ success rate, and alterations of a few nucleotides can have a
huge impact on the MMEJ efﬁciency.17 This could be an explanation
for the difference in the measured luciferase activity between the
PAMin and PAMout donor vectors, and an indication that MMEJ
is the primary repair process active here (Figure 4B). An integration
of both constructs via NHEJ would lead to similar results because no
microhomology is required.
Figure 4. Quantification of the Genome-Editing
Activity by Using the Relative Luciferase Activity
Measurement
(A) Luciferase expression was verified by western blot with
a luciferase-specific antibody. Only in lane 3 with gRNA,
template, and Cas9 protein expression, a light luciferase
band was visible. (B) RLU measured as a function of
different combinations of gRNAs, Cas9 expression
plasmid, and PAMin template DNA. Controls lack one of
the necessary plasmids. (C) Comparison of PAMin versus
PAMout template plasmid. The PAMout template plasmid
results in 100% higher luciferase signal. (D) Influence of the
DSB introduction either upstream, downstream, or at both
sides of the template plasmid. The DSB induced by g3
RNA is more important than the one induced by the g4
RNA. All experiments were performed at least in tripli-
cates. Error bars indicate the SD of the data set.
www.moleculartherapy.orgThe upstream or downstream cleavage of the luciferase gene within
the donor template also results in differences in repair efﬁciency.
The downstream cleavage is linked to decreased luciferase activity
levels, while the upstream cleavage results in similar luciferase activity
levels as the double-cut experiment. In the case of NHEJ, both single-
cut experiments would result in lower levels of luciferase activity,
because the donor plasmid backbone would have been incorporated
into the target site either between the CMV promotor and the lucif-
erase gene or following the luciferase gene, but in front of the polya-
denylation signal, both resulting in suboptimal mRNA processing.
The reason for the downstream cleavage with lower levels of luciferase
activity signaling remains unknown, but may potentially be associ-
ated with a negative inﬂuence of the very long donor plasmid back-
bone on the single-strand invasion during the homology-based
DNA repair.
The cellular RNA processing machinery in eukaryotes is obviously
capable of producing active gRNAs that allow the cut by Cas9 at
the desired locus. This has been shown in many experiments
before, and it is assumed that endogenous mammalian RNases
assist in pre-crispr RNA (crRNA) maturation.24 However, whether
the mammalian RNase system enables optimal processing orMolecular Twhether this feature is also a point where efﬁ-
cacy could be optimized was not clear. We
showed that high amounts of Csy4, which
cut the pre-crRNA between gRNA1 and
gRNA2, increased the measured luciferase ac-
tivity in our experiments. However, the
increased amount of enzyme did not change
the ratios within the experiments, which
implies a pre-crRNA processing with endoge-
nous RNases in HEK293 cells. The cleavage
rates for g1 and g2 alone were analyzed in
preliminary assays with the trafﬁc light
reporter system (TLR)34 to ensure their activ-
ity (data not shown). Therefore, if multiplexCRISPR/Cas systems are used in therapeutic settings, the addition
of the cutting enzyme to process the different gRNAs may be
useful.
All different mhs lengths (5, 15, 20, 30, and 50 bp) within
the template DNA resulted in signiﬁcant repair activity at
the RPGR-ORF15 locus. The data are in line with the results
reported earlier in budding yeast.17,20 Interestingly, the plasmid
donor with an mhs length of 5 bp was found to be the best among
the ones tested, followed by the 15-bp mhs length. However, our
results differed from that of Tadi and colleagues,20 who tested
mhs of 5, 8, 10, 13, 16, 19, and 22 bp in DSB repair during mito-
chondrial DNA lesions and reported an enhanced efﬁciency of
MMEJ with the increase in the length of the mhs. The reasons
for the highest repair activity measured with the shortest mhs
could be because of simple MMEJ being active at that particular
site, as opposed to the DNA synthesis-dependent (SD)-MMEJ
mechanisms that usually occur with the larger mhs.35–37 It could
also be a mixture of MMEJ and NHEJ mechanisms, which is
currently under intensive exploration by the authors. Knocking
down key proteins in either pathway should shed some light on
these correlations.herapy: Nucleic Acids Vol. 11 June 2018 411
Figure 5. Improvement of Guide RNA Processing in Multiplex CRISPR/Cas9
Applications
A plasmid coding the bacterial RNase Csy4 was added to the triple transfection to
process the Cas9 guide RNAs (see also Figure 2A). Addition of Csy4 increased the
Luciferase signal by 100%, indicating that cellular RNases are only partially capable
of processing multiple guide RNAs in multiplex CRISPR/Cas9 applications. Error
bars indicate the SD of the data set.
Molecular Therapy: Nucleic AcidsThe stepwise development of the reporter system started with an
episomal-based assay using ﬂuorescent reporter proteins that was
optimized further into a luciferase-based assay on the genomic level
and proved to be promising as a sensitive method to measure DNA
repair efﬁciencies in targeted gene-editing approaches. We used the
system at the locus of the RPGR gene, but it can also be used with
therapeutically relevant DNA sequences in any target cells assuming
that DNA delivery is established. After establishing the best strategy
for each disease model, the system may be further evaluated in vivo
in newly generated animal models.
MATERIALS AND METHODS
Cloning Vectors for Episomal-Based Assay
The GFP AP pEGFP-N1 is commercially available from Invitrogen.
The BamHI/KpnI (upstream) and MfeI/XbaI (downstream) were
used for cloning cassettes harboring the mhs. The donor plasmid
with BFP is based on the pSQT1313 vector (Addgene plasmid
53370). BFP was incorporated via BamHI and XhoI cleavage sites.412 Molecular Therapy: Nucleic Acids Vol. 11 June 2018The sitesNheI and BamHI upstream of BFP and the sites downstream
XhoI and PciI are recruited for cloning the microhomology sequences
with Cas9 recognitions sites. The two gRNAs for Cas9 are cloned into
the pSQT1313 vector as described by Tsai et al.38 The sequences are
listed in Table 1.
Transfection of Vectors for the Episomal-Based Assay
HEK293T cells were seeded in six-well plates at a density of
5  105 cells per well and cultured in DMEM supplemented with
10% fetal bovine serum, penicillin/streptomycin (PAN Biotech,
Aidenbach, Germany), and L-glutamine (200 mM) (PAN Biotech).
After 24 hr, cells were transfected using 200 mL of polyethyleni-
mine (PEI) mix (pH 7; 0.1 g PEI/L) in addition with 100 mL of
150 mM NaCl with 600 ng of addressed target within the TLR3
system and 600 ng of each nuclease, and additionally 300 ng of
gRNA in case of Cas9-FokI. The transfection reactions were ﬁlled
up with pET-19b or circular pTOPO-TA empty vector (Novagen/
Merck, USA/Thermo Fisher, Darmstadt, Germany) to 1.8 mg of
DNA. After 6 hr, the medium was substituted, and cells were
harvested 72 h posttransfection; the number of BFP-positive cells
was determined by ﬂow cytometry (FACS Canto Calibur; BD
Biosciences, USA).
Generation of the HEK293-mORF15 Stable Cell Line
The ORF15 exon from the mouse RPGR gene [AL671042 (gb),
Riken cDNA clone (ImaGenes)], containing four point mutations
that are unrelated to this study, was cloned into the pcDNA 3.1
() vector, under the control of a CMV promoter (Invitrogen/
Thermo Fisher Scientiﬁc, USA). Four micrograms of the vector
was linearized with EcoRI and then transfected into HEK293 cells
in a six-well plate as mentioned earlier. 48 h following the transfec-
tion, 0.5 mg/mL Geneticin (Life Technologies) was added to the
medium for selection. Surviving cell foci were picked and transferred
to 24-well plates. The selection process was repeated twice. The inte-
gration was analyzed using automated DNA sequencing by Sanger
methods. Multiple integrations of RPGR-ORF15, if any, were not
analyzed.
Vectors for Transfection in Stable HEK293-mORF15
The px459 vector [pSpCas9(BB)-2A-Puro (PX459) V2.0; Addgene
plasmid 62988] was used to cleave the donor plasmid containing
the luciferase gene. The gRNA was cloned into the vector as
described by Ran et al.39 The gRNAs (g1 and g2) targeting the
RPGR-mORF15 sequence within the genome were cloned into the
pSQT1313 vector as described by Tsai et al.38 All Cas9 target sites
are listed in Table 1, with the polyspacer adjacent motif (PAM) sites
being underlined. The donor plasmid is based on sequences that
have homology to the RPGR-mORF15 and are between the length
of 5 and 50 bp.
Transfection and Lysis of HEK293-mORF15 Cells, Western Blot,
and Measurement of Luciferase Activity
HEK293-mORF15 cells were seeded in six-well plates at a density of
5  105 cells per well with DMEM and Geneticin (0.5 mg/mL), and
Figure 6. Efficacy of Luciferase Integration in
Dependence of the Length of the Microhomologous
Sequences in the Template Plasmid
(A) Schematic representation of the different mhs sequences
supplied with the luciferase donor templates iaPAMout. (B)
Quantification of luciferase integration following mhs-medi-
ated DSB repair. Different mhs length results in significantly
different RLU levels, with 5 bp mhs being by far the most
efficient variant. *p < 0.001 (Holm-Sidak pairwise multiple
comparison). Error bars indicate the SD of the data set.
www.moleculartherapy.orgthe quadruple transfection with PEI was performed as described
earlier. Different plasmid concentrations were used and are listed in
the Results. Cells were harvested 48–72 hr posttransfection using
the cell lysis buffer for luciferase assays (Promega, Mannheim,
Germany). Additionally, the cell lysates were snap chilled twice before
pipetting 20 mL of the cleared lysate (17,000 rpm; 5 min; 4C) into
COSTAR Lumiplates Flat White (Corning, Berlin, Germany).
Protein samples were processed for western blot application. Forty
micrograms of total protein was loaded onto two identical
SDS-PAGE gels and migrated along their molecular weight. Primary
antibodies against luciferase (rabbit anti-RLuc, ab187338; Abcam,
Cambridge, UK) and GAPDH (rabbit anti-glycerine aldehyde
3-phosphate dehydrogenase [GAPDH]; Cell Signaling, Frankfurt,
Germany) were used, following the secondary antibody fused to
HR peroxidase (goat anti-rabbit IgG-HRP; Sigma, Darmstadt,
Germany). Chemiluminescence detection assay was performedwith the ECL peroxidase detection kit (Amersham Bioscience, Buck-
inghamshire, UK).
The luciferase activity was measured after adding the substrate
h-Coelenterazine (NanoLight, Pinetop USA) in 500 mL of
NanoLight-Fuel Solvent and diluted in 1:100 in 1 PBS. 100 mL of
the Renilla luciferase substrate solution was used for each well, and
the measurements were recorded using Tecan Inﬁnite M1000 Pro
plate reader (Tecan, Groeding, Austria) with open ﬁlters and an
integration time of 1 s to collect photons produced by the luciferase
(photons/s c= RLU).
Statistical Analysis
All of the experiments were performed and measured at least in
triplicate; Student’s paired t test and the Holm-Sidak method were
used to compare the results. The p value for each dataset is ﬁxed inde-
pendently, as mentioned in the respective bar graphs/ﬁgures.Molecular Therapy: Nucleic Acids Vol. 11 June 2018 413
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